After the treatment of urogenital cancer, a person may develop lymphoedema of the leg(s) and/ or midline region. Clinical symptoms include abnormal tissue swelling, sensation of limb heaviness, erythema, pain, and impaired limb function. Lymphoedema can have a negative impact on quality of life (QoL) and the impact of lymphoedema on the cancer treatment decision making process is underestimated. A limited number of studies have evaluated the incidence rate of midline and leg lymphoedema after surgery for urogenital cancers and have investigated the prognostic variables. In addition, to the researchers knowledge, no evidence exists regarding which (combination of) clinical measuring methods are most sensitive to detect early lymphoedema at the lower limbs after the treatment of urogenital cancer. Therefore, in this prospective observational study, the epidemiology (i.e. incidence/ prevalence rate and prognostic variables) and the detection methods of lower limb lymphoedema after pelvic lymph node dissection for urogenital cancer will be investigated. Additionally, the epidemiology of nocturia and nocturnal polyuria will be studied (since this information is also missing in literature).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cumulative incidence rate of lower limb lymphoedema after urogenital cancer (i.e. number of patients with newly diagnosed lower limb lymphoedema) 6 weeks post-surgery
Timeframe: 6 weeks post-surgery
Cumulative incidence rate of lower limb lymphoedema after urogenital cancer (i.e. number of patients with newly diagnosed lower limb lymphoedema) 6 months post-surgery
Timeframe: 6 months post-surgery
Cumulative incidence rate of lower limb lymphoedema after urogenital cancer (i.e. number of patients with newly diagnosed lower limb lymphoedema) 12 months post-surgery
Timeframe: 12 months post-surgery
Prognostic value of 'baseline age' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of ' Baseline fat mass' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of ' Baseline physical activity level' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of ' Baseline educational level' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of ' baseline comorbidities' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'type of cancer' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'Tumor stage' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'Lymph node stage' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'number of positive lymph nodes' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'postoperative complications' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'type of lymph node dissection' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'number of lymph nodes removed' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery
Prognostic value of 'Adjuvant Radiotherapy' for the development of lower limb lymphoedema at 12 months post-surgery.
Timeframe: 12 months post-surgery